Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Dec 20;1(1):e5. doi: 10.1097/HS9.0000000000000005

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0

PMC Copyright notice

Kaplan-Meier estimates for the intention-to-treat set. (A) Progression-free survival. (B) Overall survival. BEACOPP-14 = bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in dose-dense variant, eBEACOPP = bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated dose, HR = hazard ratio, PFS = progression-free survival. (a) Hazard ratios adjusted for stratification factors age, sex, Ann Arbor stage, international prognostic score and hemoglobin level.